A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : NAC / N-acetylcarnosine

[Related PubMed/MEDLINE]
Total Number of Papers: 16
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   NAC  (>> Co-occurring Abbreviation)
Long Form:   N-acetylcarnosine
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Investigation of a new horizon antifungal activity with enhancing the antimicrobial efficacy of ciprofloxacin and its binary mixture via their encapsulation in nanoassemblies: in vitro and in vivo evaluation. CIP, DPC, HP-beta-CD
2018 An approach to revolutionize cataract treatment by enhancing drug probing through intraocular cell line. SLN
2018 Novel NAC-loaded poly(lactide-co-glycolide acid) nanoparticles for cataract treatment: preparation, characterization, evaluation of structure, cytotoxicity, and molecular docking studies. NPs, PLGA
2017 N-acetylcarnosine (NAC) drops for age-related cataract. AMED, ASCRS, CINAHL, ESCRS, ICTRP, WHO
2014 Biomarkers of oxidative stress and cataract. Novel drug delivery therapeutic strategies targeting telomere reduction and the expression of telomerase activity in the lens epithelial cells with N-acetylcarnosine lubricant eye drops: anti-cataract which helps to prevent and treat cataracts in the eyes of dogs and other animals. iron, LECs, ROS
2013 Oxaliplatin complexes with carnosine and its derivatives: in vitro cytotoxicity, mass spectrometric and computational studies with a focus on complex fragmentation. OxPt
2011 Designation of imidazole-containing dipeptides as pharmacological chaperones. AMD, OCD
2010 Ability of N-acetylcarnosine to protect lens crystallins from oxidation and oxidative damage by radical probe mass spectrometry (RP-MS). RP-MS
2009 N-Acetylcarnosine and histidyl-hydrazide are potent agents for multitargeted ophthalmic therapy of senile cataracts and diabetic ocular complications. ---
10  2009 N-Acetylcarnosine sustained drug delivery eye drops to control the signs of ageless vision: glare sensitivity, cataract amelioration and quality of vision currently available treatment for the challenging 50,000-patient population. ---
11  2009 Potentiation of intraocular absorption and drug metabolism of N-acetylcarnosine lubricant eye drops: drug interaction with sight threatening lipid peroxides in the treatment for age-related eye diseases. LPO
12  2008 Ocular drug metabolism of the bioactivating antioxidant N-acetylcarnosine for vision in ophthalmic prodrug and codrug design and delivery. ---
13  2006 Biological activities of the natural imidazole-containing peptidomimetics n-acetylcarnosine, carcinine and L-carnosine in ophthalmic and skin care products. LPO
14  2005 Analysis of lipid peroxidation and electron microscopic survey of maturation stages during human cataractogenesis: pharmacokinetic assay of Can-C N-acetylcarnosine prodrug lubricant eye drops for cataract prevention. HPLC, LPO
15  2004 Rejuvenation of visual functions in older adult drivers and drivers with cataract during a short-term administration of N-acetylcarnosine lubricant eye drops. ---
16  2002 Efficacy of N-acetylcarnosine in the treatment of cataracts. ---